[go: up one dir, main page]

CA2533113A1 - Fragments solubles de la glycoproteine de spicule sras-cov - Google Patents

Fragments solubles de la glycoproteine de spicule sras-cov Download PDF

Info

Publication number
CA2533113A1
CA2533113A1 CA002533113A CA2533113A CA2533113A1 CA 2533113 A1 CA2533113 A1 CA 2533113A1 CA 002533113 A CA002533113 A CA 002533113A CA 2533113 A CA2533113 A CA 2533113A CA 2533113 A1 CA2533113 A1 CA 2533113A1
Authority
CA
Canada
Prior art keywords
thr
ser
leu
phe
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002533113A
Other languages
English (en)
Inventor
Dimiter S. Dimitrov
Xiaodong Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2533113A1 publication Critical patent/CA2533113A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002Coronaviridae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002533113A 2003-07-21 2004-07-20 Fragments solubles de la glycoproteine de spicule sras-cov Abandoned CA2533113A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48916603P 2003-07-21 2003-07-21
US60/489,166 2003-07-21
US52464203P 2003-11-25 2003-11-25
US60/524,642 2003-11-25
PCT/US2004/023345 WO2005010034A1 (fr) 2003-07-21 2004-07-20 Fragments solubles de la glycoproteine de spicule sras-cov

Publications (1)

Publication Number Publication Date
CA2533113A1 true CA2533113A1 (fr) 2005-02-03

Family

ID=34107787

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002533113A Abandoned CA2533113A1 (fr) 2003-07-21 2004-07-20 Fragments solubles de la glycoproteine de spicule sras-cov

Country Status (5)

Country Link
EP (1) EP1648927A1 (fr)
AU (1) AU2004259750A1 (fr)
CA (1) CA2533113A1 (fr)
TW (1) TW200510450A (fr)
WO (1) WO2005010034A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240515A1 (en) * 2003-07-21 2006-10-26 Dimitrov Dimiter S Soluble fragments of the SARS-CoV spike glycoprotein
TW200515917A (en) * 2003-09-15 2005-05-16 Us Government Methods and compositions for the generation of a protective immune response against SARS-COV
ES2437858T3 (es) * 2003-11-04 2014-01-14 The Administrators Of The Tulane Educational Fund Método para impedir la fusión virus:célula inhibiendo la función de la región de inicio de fusión en virus de ARN que tienen proteínas de envoltura fusogénicas de membrana de clase I
WO2005054469A1 (fr) * 2003-12-05 2005-06-16 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Anticorps monoclonaux anti-sars
WO2006071250A2 (fr) * 2004-04-05 2006-07-06 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Fragments solubles de la glycoproteine de spicule de cov-sras
TWI293957B (en) * 2004-07-21 2008-03-01 Healthbanks Biotech Co Ltd A superantigen fusion protein and the use thereof
EP1749833A1 (fr) 2005-08-05 2007-02-07 Healthbanks Biotech Co., Ltd. Superantigènes dérivés de la protéine à pointe E2 du coronavirus du SRAS
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
BRPI0813922A2 (pt) 2007-06-25 2017-05-09 Autoimmune Tech Llc composições de inibição de influenza e métodos.
CN113264991B (zh) * 2020-01-31 2023-05-16 上海桀蒙生物技术有限公司 病毒疫苗的制备方法及药物组合物
EP3869200A1 (fr) 2020-02-20 2021-08-25 Euroimmun Medizinische Labordiagnostika AG Procédé et réactifs pour le diagnostic du sars-cov-2
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
WO2021195089A1 (fr) * 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Protéines de fusion de l'antigène fc-coronavirus et acides nucléiques, vecteurs, compositions et procédés d'utilisation associés
WO2021207014A2 (fr) * 2020-04-06 2021-10-14 Phylex Biosciences, Inc. Réactifs et procédés de prévention, de traitement ou de limitation d'une infection à coronavirus du syndrome respiratoire aigu sévère (sras)
EP3892298A1 (fr) * 2020-04-09 2021-10-13 PreviPharma Consulting GmbH Épitopes ayant une homologie de séquence avec la sous-unité de protéine de spicule de coronavirus et leurs utilisations
CN113527444B (zh) * 2020-04-13 2022-12-27 中国科学院微生物研究所 与新型冠状病毒的抗体有效结合的表位
CN112010966B (zh) * 2020-05-15 2021-03-19 潍坊医学院 一种针对新冠病毒棘突蛋白非rbd区的单克隆抗体及其应用
CN113797326B (zh) * 2020-06-17 2024-01-19 上海君实生物医药科技股份有限公司 一种预防冠状病毒引起疾病的疫苗
EP3943944A1 (fr) * 2020-07-24 2022-01-26 Consejo Superior de Investigaciones Científicas (CSIC) Procédé multiplexé de cytométrie en flux pour la détection d'anticorps sars-cov-2
WO2022029494A1 (fr) * 2020-08-04 2022-02-10 Abbott Rapid Diagnostics International Unlimited Company Analyses pour la détection de sars-cov-2
CN114057842A (zh) * 2020-08-07 2022-02-18 清华大学 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途
CN113698487B (zh) * 2021-08-16 2022-08-19 中国科学院微生物研究所 抗人ace2单克隆抗体及其应用
CN113633764B (zh) * 2021-09-02 2024-05-14 中国食品药品检定研究院 一种含佐剂的新冠dna疫苗

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2135201A1 (fr) * 1992-05-08 1993-11-25 Timothy J. Miller Vaccin universel contre le coronavirus

Also Published As

Publication number Publication date
AU2004259750A1 (en) 2005-02-03
WO2005010034A1 (fr) 2005-02-03
TW200510450A (en) 2005-03-16
AU2004259750A2 (en) 2005-02-03
EP1648927A1 (fr) 2006-04-26

Similar Documents

Publication Publication Date Title
US20060240515A1 (en) Soluble fragments of the SARS-CoV spike glycoprotein
CA2533113A1 (fr) Fragments solubles de la glycoproteine de spicule sras-cov
US8092994B2 (en) Human virus causing respiratory tract infection and uses thereof
CN117957016A (zh) Sars-cov-2与流感联合疫苗
CA2526128C (fr) Compositions vaccinales d'adn contre le syndrome respiratoire aigu severe et leurs procedes d'utilisation
US20060286124A1 (en) Vaccine compositions and methods of treating coronavirus infection
RU2764740C1 (ru) Биспецифическое антитело против вируса бешенства и его применение
US20070116716A1 (en) Sars coronavirus s proteins and uses thereof
CA2569142A1 (fr) Vaccins contre le sras et procedes de production d'anticorps tres puissants
JP2008529504A (ja) 重症急性呼吸器症候群関連コロナウイルスに対する中和モノクローナル抗体
US11135280B2 (en) Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity
TWI303249B (en) Receptor binding polypeptides
CN101098710A (zh) 产生高度有效抗体的sars疫苗和方法
EP2155777A2 (fr) Formes solubles et ancrées sur membrane de protéines de sous-unité du virus lassa
TW200806791A (en) Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus
WO2006007795A1 (fr) Nouveau virus humain provoquant une infection des voies respiratoires et son utilisation
US20020127245A1 (en) Canine coronavirus S gene and uses therefor
CN110913891A (zh) 沙粒病毒单克隆抗体和用途
Hesse Characterization of the binding properties of the Avian Coronavirus spike protein

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued